TrialDiabetes, obesity & metabolism2022

Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.

Lorenzo Piemonti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.